Treatment with interleukin (IL) inhibitors appear to be associated with an increased risk of serious infections, opportunistic infections and cancer in rheumatology patients, according to a systemic review and meta-analysis published in in JAMA Network Open this fall. This study was selected by Rheumatology Network as among the most noteworthy of 2019. Learn more in this slideshow.
There were some noteworthy achievements in rheumatology this year: A biosimilar was approved for rheumatoid arthritis, a workable treatment was discovered for systemic sclerosis lung disease, treatment guidelines were penned for JIA-related uveitis and more. In this slideshow, we highlight a few of these achievements. (©Angkhan,AdobeStock)